2023 ESMO Posters
The molecules presented are investigational. Safety and efficacy have not been established.
BL-M07D1, a HER2 antibody-drug conjugate (ADC), in subjects with locally advanced or metastatic HER2 expressing breast cancer (BC) and other solid tumors: A phase I, multicenter, open-lable study
© 2023 SystImmune, Inc. All rights reserved.